



**CERTIFICATE OF MAILING**

I hereby certify that this paper and every  
paper referred to therein as being enclosed  
is being deposited with the U.S. Postal  
Service as first class mail, postage prepaid,  
in an envelope addressed to: Commissioner of  
Patents & Trademarks, Washington, DC 20231,  
on October 6, 1995 (Date of Deposit)  
10/10/95 A. Stanini  
Date Name

9/120  
**RECEIVED** #2

NOV 03 1995

GROUP 1800

WB  
11/13/95

1010/16959 US4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Howard L. Weiner et al.

Serial No.: 08/469,492 Examiner:

Filed: 06/06/95 Group Art Unit: 1802 ~~1203~~

For: BYSTANDER SUPPRESSION OF AUTOIMMUNE DISEASES

1802  
STAPLES

**INFORMATION DISCLOSURE STATEMENT IN CONTINUING APPLICATION**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

In order to comply with discretionary regulations 37 CFR 1.97  
and 1.98, attached is one or more forms listing the documents made of  
record in the U.S. Patent and Trademark Office during prosecution of the  
parent application Serial No. 07/843,752 filed February 28, 1992, now

abandoned. Copies of the listed documents except for WO 95/00127 can be found in the file of U.S. Patent Application Serial No. 08/472,017, filed June 6, 1995, the Rule 62 continuation of abandoned application Serial No. 07/843,752, and are not submitted as permitted by Rule 1.98(d). WO 95/00127 is submitted herewith. The documents listed contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of

the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

  
Adda C. Gogoris  
Registration No. 29,714  
Attorney for Applicants

DARBY & DARBY P.C.  
805 Third Avenue  
New York, N.Y. 10022  
(212) 527-7700